Bronnen:
Bellingan G, Jacono F, Bannard-Smith J, Brealey D, Meyer N, Thickett D, et al. Primary analysis of a phase 1/2 study to assess multiStem® cell therapy, a regenerative advanced therapy medicinal product (ATMP), in acute respiratory distress syndrome (MUST-ARDS). Am J Resp Crit Care Med. 2019;199:A7353.
Bellingan G, Jacono F, Bannard-Smith J, Brealey D, Meyer N, Thickett D, et al. Primary analysis of a phase 1/2 study to assess multiStem® cell therapy, a regenerative advanced therapy medicinal product (ATMP), in acute respiratory distress syndrome (MUST-ARDS). Am J Resp Crit Care Med. 2019;199:A7353.